Precigen, Inc. (NASDAQ:PGEN - Get Free Report)'s stock price rose 7.9% during mid-day trading on Monday . The stock traded as high as $1.97 and last traded at $1.98. Approximately 1,070,190 shares were traded during mid-day trading, a decline of 27% from the average daily volume of 1,468,327 shares. The stock had previously closed at $1.83.
Analyst Ratings Changes
PGEN has been the topic of several research analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Precigen in a research note on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $6.00 target price on shares of Precigen in a research report on Thursday, March 20th. Wall Street Zen raised Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $6.00 target price on shares of Precigen in a research report on Thursday, June 12th.
Read Our Latest Research Report on Precigen
Precigen Trading Down 1.1%
The firm has a market cap of $537.23 million, a P/E ratio of -3.25 and a beta of 1.78. The firm has a 50-day simple moving average of $1.50 and a 200-day simple moving average of $1.51.
Precigen (NASDAQ:PGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. The firm had revenue of $1.34 million during the quarter, compared to analyst estimates of $0.50 million. Research analysts predict that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.
Institutional Trading of Precigen
Several hedge funds and other institutional investors have recently made changes to their positions in PGEN. BNP Paribas Financial Markets purchased a new stake in shares of Precigen during the 4th quarter valued at $27,000. Envestnet Asset Management Inc. lifted its holdings in shares of Precigen by 29.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 5,915 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Precigen during the 4th quarter valued at $35,000. Apella Capital LLC purchased a new position in Precigen in the 1st quarter worth $40,000. Finally, RPO LLC purchased a new position in Precigen in the 4th quarter worth $47,000. Hedge funds and other institutional investors own 33.51% of the company's stock.
Precigen Company Profile
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Featured Stories
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
